Checkpoint Inhibitor Refractory Cancer Global Market Report 2025

Description

Checkpoint inhibitor refractory cancer refers to cancers that do not respond to immune checkpoint inhibitors, such as PD-1, PD-L1, or CTLA-4 blockers. This resistance can be primary, where there is no initial response, or acquired, where the cancer progresses after an initial benefit. Managing these cases typically requires alternative approaches, including combination immunotherapy, targeted therapies, or novel experimental strategies.

The primary therapies for checkpoint inhibitor refractory cancer include immune checkpoint inhibitors, combination therapies, and targeted therapies. Immune checkpoint inhibitors are drugs that help the immune system recognize and attack cancer cells by blocking proteins that inhibit immune cell function. These therapies are used for various cancer types, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, triple-negative breast cancer (TNBC), colorectal cancer, and others. Their mechanisms of action include programmed cell death protein-1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, among others. Routes of administration include intravenous (IV) and oral, with distribution through hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The checkpoint inhibitor refractory cancer market research report is one of a series of new reports from The Business Research Company that provides checkpoint inhibitor refractory cancer market statistics, including checkpoint inhibitor refractory cancer industry global market size, regional shares, competitors with a checkpoint inhibitor refractory cancer market share, checkpoint inhibitor refractory cancer market segments, market trends and opportunities, and any further data you may need to thrive in the checkpoint inhibitor refractory cancer industry. This checkpoint inhibitor refractory cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The checkpoint inhibitor refractory cancer market size has grown rapidly in recent years. It will grow from $32.81 billion in 2024 to $36.69 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth during the historic period can be attributed to the rising prevalence of cancer, increasing awareness of checkpoint inhibitors, expansion of cancer screening programs, growth in clinical trial activities, and rising demand for personalized treatments.

The checkpoint inhibitor refractory cancer market size is expected to see rapid growth in the next few years. It will grow to $56.64 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth during the forecast period can be attributed to the increasing number of cancer diagnoses, rising demand for personalized medicine, expanding indications for checkpoint inhibitors, a growing geriatric population, and greater use of biomarkers for patient selection. Key trends in this period include advancements in combination therapies, development of next-generation checkpoint inhibitors, integration of AI in treatment planning, introduction of oral checkpoint inhibitors, and progress in personalized cancer vaccines.

The rising incidence of cancer is anticipated to drive the growth of the checkpoint inhibitor refractory cancer market in the coming years. Cancer is a disease characterized by the uncontrolled growth and division of abnormal cells in the body. The increase in cancer cases is largely attributed to an aging population, as longer life expectancy raises the likelihood of developing cancer over time. Identifying checkpoint inhibitor refractory cancer is crucial in cancer management, as it allows early detection of treatment resistance, enabling clinicians to adjust therapy promptly and explore alternative approaches that may improve patient outcomes. For example, in February 2025, the United Nations, a US-based intergovernmental organization, reported that an estimated 2.3 million new breast cancer cases were diagnosed in 2022, resulting in 670,000 deaths, with global projections indicating a 38% increase in cases and a 68% rise in annual deaths by 2050. Consequently, the growing incidence of cancer is supporting the expansion of the checkpoint inhibitor refractory cancer market.

Key players in the checkpoint inhibitor refractory cancer market are focusing on developing innovative solutions, such as dual selective inhibitors, to reduce the risk of drug resistance by targeting two critical pathways involved in disease progression. Dual selective inhibitors are compounds that simultaneously block two distinct biological targets or pathways while minimizing effects on unrelated pathways. For instance, in March 2025, Pliant Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, announced interim Phase 1 data for PLN-101095 in patients with immune checkpoint inhibitor-refractory advanced solid tumors. The data demonstrated promising early activity and a manageable safety profile. At the highest tested dose of 1,000 mg twice daily combined with pembrolizumab, the trial reported a 50% objective response rate, including confirmed partial responses in patients with non-small cell lung cancer, cholangiocarcinoma, and melanoma, showing substantial tumor reductions. PLN-101095 was generally well tolerated, with most treatment-emergent adverse events being mild to moderate. The study is ongoing, with higher-dose cohorts currently enrolling and additional data expected by the end of 2025.

In October 2023, Bristol-Myers Squibb Company, a US-based pharmaceutical firm, acquired Mirati Therapeutics Inc. for an undisclosed amount. Through this acquisition, Bristol-Myers Squibb aims to strengthen and diversify its oncology portfolio by integrating Mirati's innovative cancer therapies and clinical-stage assets, particularly those targeting KRAS-mutated cancers and checkpoint inhibitor refractory cancers. Mirati Therapeutics Inc. is a US-based company specializing in therapies designed specifically for checkpoint inhibitor refractory cancers.

Major players in the checkpoint inhibitor refractory cancer market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co. Inc., AbbVie Inc., Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline Plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Exelixis Inc., Exicure Inc., ImmunityBio Inc., ENB Therapeutics Inc., Kartos Therapeutics Inc., and Pliant Therapeutics Inc.

North America was the largest region in the checkpoint inhibitor refractory cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in checkpoint inhibitor refractory cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the checkpoint inhibitor refractory cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The checkpoint inhibitor refractory cancer market includes revenues earned by entities by providing services such as diagnostic and biomarker services, clinical trials and research services, specialized oncology treatment services, and patient support and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The checkpoint inhibitor refractory cancer market consists of sales of tumor-infiltrating lymphocyte (TIL) therapy kits, genomic sequencing panels, tumor organoids, drug discovery tools, and bispecific antibodies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Checkpoint Inhibitor Refractory Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on checkpoint inhibitor refractory cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for checkpoint inhibitor refractory cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The checkpoint inhibitor refractory cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Therapy: Immune Checkpoint Inhibitors; Combination Therapies; Targeted Therapies
2) By Cancer Type: Non-Small Cell Lung Cancer (NSCLC); Melanoma; Renal Cell Carcinoma (RCC); Head And Neck Squamous Cell Carcinoma (HNSCC); Urothelial Carcinoma; Triple-Negative Breast Cancer (TNBC); Colorectal Cancer; Other Cancer Types
3) By Mechanism Of Action: Programmed Cell Death Protein (PD)-1 Inhibitors; Programmed Death-Ligand (PD)-L1 Inhibitors; Cytotoxic T-Lymphocyte-Associated Protein (CTLA)-4 Inhibitors; Other Mechanism Of Actions
4) By Administration Route: Intravenous (IV); Oral
5) By End-User: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Immune Checkpoint Inhibitors (ICIs): PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4 Inhibitors
2) By Combination Therapies: Checkpoint Inhibitor + Chemotherapy; Checkpoint Inhibitor + Targeted Therapy; Checkpoint Inhibitor + Other Immunotherapies; Dual Checkpoint Inhibitor Combinations
3) By Targeted Therapies: Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies Targeting Specific Cancer Markers
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; Merck & Co. Inc.; AbbVie Inc.; Novartis International AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC; GlaxoSmithKline Plc; Eli Lilly and Company; Gilead Sciences Inc.; Amgen Inc.; Regeneron Pharmaceuticals Inc.; Eisai Co. Ltd.; Exelixis Inc.; Exicure Inc.; ImmunityBio Inc.; ENB Therapeutics Inc.; Kartos Therapeutics Inc.; Pliant Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37722

1. Executive Summary

2. Checkpoint Inhibitor Refractory Cancer Market Characteristics

3. Checkpoint Inhibitor Refractory Cancer Market Trends And Strategies

4. Checkpoint Inhibitor Refractory Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Checkpoint Inhibitor Refractory Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global Checkpoint Inhibitor Refractory Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Checkpoint Inhibitor Refractory Cancer Market Growth Rate Analysis
5.4. Global Checkpoint Inhibitor Refractory Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Checkpoint Inhibitor Refractory Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Checkpoint Inhibitor Refractory Cancer Total Addressable Market (TAM)

6. Checkpoint Inhibitor Refractory Cancer Market Segmentation

6.1. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Checkpoint Inhibitors
Combination Therapies
Targeted Therapies
6.2. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non-Small Cell Lung Cancer (NSCLC)
Melanoma
Renal Cell Carcinoma (RCC)
Head And Neck Squamous Cell Carcinoma (HNSCC)
Urothelial Carcinoma
Triple-Negative Breast Cancer (TNBC)
Colorectal Cancer
Other Cancer Types
6.3. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Programmed Cell Death Protein (PD)-1 Inhibitors
Programmed Death-Ligand (PD)-L1 Inhibitors
Cytotoxic T-Lymphocyte-Associated Protein (CTLA)-4 Inhibitors
Other Mechanism Of Actions
6.4. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous (IV)
Oral
6.5. Global Checkpoint Inhibitor Refractory Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.6. Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Immune Checkpoint Inhibitors (ICIs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
6.7. Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Combination Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Checkpoint Inhibitor + Chemotherapy
Checkpoint Inhibitor + Targeted Therapy
Checkpoint Inhibitor + Other Immunotherapies
Dual Checkpoint Inhibitor Combinations
6.8. Global Checkpoint Inhibitor Refractory Cancer Market, Sub-Segmentation Of Targeted Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tyrosine Kinase Inhibitors (TKIs)
Monoclonal Antibodies Targeting Specific Cancer Markers

7. Checkpoint Inhibitor Refractory Cancer Market Regional And Country Analysis

7.1. Global Checkpoint Inhibitor Refractory Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Checkpoint Inhibitor Refractory Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market

8.1. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Checkpoint Inhibitor Refractory Cancer Market

9.1. China Checkpoint Inhibitor Refractory Cancer Market Overview
9.2. China Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Checkpoint Inhibitor Refractory Cancer Market

10.1. India Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Checkpoint Inhibitor Refractory Cancer Market

11.1. Japan Checkpoint Inhibitor Refractory Cancer Market Overview
11.2. Japan Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Checkpoint Inhibitor Refractory Cancer Market

12.1. Australia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Checkpoint Inhibitor Refractory Cancer Market

13.1. Indonesia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Checkpoint Inhibitor Refractory Cancer Market

14.1. South Korea Checkpoint Inhibitor Refractory Cancer Market Overview
14.2. South Korea Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Checkpoint Inhibitor Refractory Cancer Market

15.1. Western Europe Checkpoint Inhibitor Refractory Cancer Market Overview
15.2. Western Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Checkpoint Inhibitor Refractory Cancer Market

16.1. UK Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Checkpoint Inhibitor Refractory Cancer Market

17.1. Germany Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Checkpoint Inhibitor Refractory Cancer Market

18.1. France Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Checkpoint Inhibitor Refractory Cancer Market

19.1. Italy Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Checkpoint Inhibitor Refractory Cancer Market

20.1. Spain Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market

21.1. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market Overview
21.2. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Checkpoint Inhibitor Refractory Cancer Market

22.1. Russia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Checkpoint Inhibitor Refractory Cancer Market

23.1. North America Checkpoint Inhibitor Refractory Cancer Market Overview
23.2. North America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Checkpoint Inhibitor Refractory Cancer Market

24.1. USA Checkpoint Inhibitor Refractory Cancer Market Overview
24.2. USA Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Checkpoint Inhibitor Refractory Cancer Market

25.1. Canada Checkpoint Inhibitor Refractory Cancer Market Overview
25.2. Canada Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Checkpoint Inhibitor Refractory Cancer Market

26.1. South America Checkpoint Inhibitor Refractory Cancer Market Overview
26.2. South America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Checkpoint Inhibitor Refractory Cancer Market

27.1. Brazil Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Checkpoint Inhibitor Refractory Cancer Market

28.1. Middle East Checkpoint Inhibitor Refractory Cancer Market Overview
28.2. Middle East Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Checkpoint Inhibitor Refractory Cancer Market

29.1. Africa Checkpoint Inhibitor Refractory Cancer Market Overview
29.2. Africa Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Checkpoint Inhibitor Refractory Cancer Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Checkpoint Inhibitor Refractory Cancer Market Competitive Landscape And Company Profiles

30.1. Checkpoint Inhibitor Refractory Cancer Market Competitive Landscape
30.2. Checkpoint Inhibitor Refractory Cancer Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

31. Checkpoint Inhibitor Refractory Cancer Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca PLC
31.4. GlaxoSmithKline Plc
31.5. Eli Lilly and Company
31.6. Gilead Sciences Inc.
31.7. Amgen Inc.
31.8. Regeneron Pharmaceuticals Inc.
31.9. Eisai Co. Ltd.
31.10. Exelixis Inc.
31.11. Exicure Inc.
31.12. ImmunityBio Inc.
31.13. ENB Therapeutics Inc.
31.14. Kartos Therapeutics Inc.
31.15. Pliant Therapeutics Inc.

32. Global Checkpoint Inhibitor Refractory Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Checkpoint Inhibitor Refractory Cancer Market

34. Recent Developments In The Checkpoint Inhibitor Refractory Cancer Market

35. Checkpoint Inhibitor Refractory Cancer Market High Potential Countries, Segments and Strategies

35.1 Checkpoint Inhibitor Refractory Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 Checkpoint Inhibitor Refractory Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 Checkpoint Inhibitor Refractory Cancer Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer